Interferon-γ therapy in two patients with progressive chronic pulmonary aspergillosis

European Respiratory Journal

Volumn 27, Issue 6, 2006, Pages 1307-1310

  Kelleher, P ^a,b   Goodsall, A ^c   Mulgirigama, A ^d   Kunst, H ^b   Henderson, D C ^a   Wilson, R ^b   Newman Taylor, A ^d   Levin, M ^c  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c ST MARY S HOSPITAL   (United Kingdom)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Chronic pulmonary Aspergillus infection; Interferon therapy

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CASPOFUNGIN; GAMMA INTERFERON; ITRACONAZOLE; PHYTOHEMAGGLUTININ; TUBERCULOSTATIC AGENT; VORICONAZOLE;

ADD ON THERAPY; ADULT; ARTICLE; ASPERGILLUS; CASE REPORT; CELL STIMULATION; COMBINATION CHEMOTHERAPY; CYTOKINE RELEASE; DATA ANALYSIS; DISEASE COURSE; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; IN VITRO STUDY; LUNG ASPERGILLOSIS; LUNG DISEASE; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BLOOD; CHRONIC DISEASE; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; IMMUNOLOGY; LUNG LAVAGE; LUNG MYCOSIS; MICROBIOLOGY; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BRONCHOALVEOLAR LAVAGE FLUID; CHRONIC DISEASE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE II; LUNG DISEASES, FUNGAL; MIDDLE AGED;

EID: 33750687527     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00021705     Document Type: Article

References (19)

1. Soubani AO, Chandrasekar PH. The clinical spectrum of pulmonary aspergillosis. Chest 1999; 121: 1989-1999.
2. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781-805.
3. Kontoyiannis DP, Bodey GP. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis 2002; 21: 161-172.
4. Romani L. Immunity to fungal infections. Nat Rev Immunol 2004; 4: 11-24.
5. Weir RE, Morgan AR, Britton WJ, Butlin CR, Dockrell HM. Development of a whole blood assay to measure T cell responses to leprosy: a new tool for immuno-epidemiological field tools of leprosy immunity. J Immunol Methods 1994; 176: 93-101.
6. Levin M, Newport MJ, D'Souza S, et al. Familial disseminated atypical mycobacterial infection in childhood: a human mycobacterial susceptibility gene. Lancet 1995; 345: 79-83.
7. Jouanguy E, Lamhamedi-Cherradi S, Altare F, et al. Partial interferon-γ receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guérin infection and a sibling with clinical tuberculosis. J Clin Invest 1997, 100: 2658-2664.
8. Doffinger R, Helbert MR, Barcenas-Morales G, et al. Autoantibodies to interferon-γ in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity. Clin Infect Dis 2004; 38: e10-e14.
9. Saraceno JL, Phelps DT, Ferro TJ, Futerfas R, Schwartz DB. Chronic necrotizing pulmonary aspergillosis: approach to management. Chest 1997, 112: 541-548.
10. Denning DW, Riniotis K, Dobrashian R, Sambatakou. H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 2003; 37: Suppl. 3, S265-S280.
11. Casanova J-L, Abel L. The human model: a genetic dissection of immunity to infection in natural conditions. Nat Rev Immunol 2004; 4: 55-65.
12. Dorman S, Picard C, Lammas D, et al. Clinical features of dominant and recessive interferon γ receptor 1 deficiencies. Lancet 2004; 364: 2113-2121.
13. Dupuis S, Jouanguy E, Al-Hajjar S, et al. Impaired response to interferon α/β and lethal viral disease in human STAT1 deficiency. Nat Genet 2003; 33: 388-391.
14. Hofflich C, Sabat R, Rosseau A, et al. Naturally occurring anti-IFN-γ autoantibody and severe infections with Mycobacterium chelonae and Burkholderia cocovenenans. Blood 2004; 103: 673-675.
15. Safdar A, Armstrong D. A novel defect in interferon-γ secretion in patients with refractory nontuberculous pulmonary mycobacteriosis. Ann Intern Med 2003; 138: 521.
16. Bernhisel-Broadbent J, Camargo EE, Jaffe HS, Lederman HM. Recombinant human interferon-γ as adjunct therapy for Aspergillus infection in a patient with chronic granulomatous disease. J Infect Dis 1991; 163: 908-911.
17. Rex JH, Bennett JE, Gallin JI, Malech HL, DeCarlos ES, Melnick DA. In vivo interferon-γ therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae. J Infect Dis 1991; 163: 849-852.
18. Ito R, Mori M, Katakura S, et al. Selective insufficiency of IFN-γ secretion in patients with the hyper-IgE syndrome. Allergy 2003; 58: 329-336.
19. Hebart H, Bollinger C, Fisch P, et al. Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies. Blood 2002; 100: 4521-4528.